EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

LIBX‐A401: A Novel Selective Inhibitor of Acyl‐CoA Synthetase Long Chain Family Member 4 (ACSL4) and Its Binding Mode

Darius Mazhari Dorooee iD, Séverine Ravez iD, Didier Vertommen iD, Nicolas Renault iD, Nicolas Papadopoulos iD, Romain Marteau iD, Emeline Charnelle, Karine Porte iD, Alexandre Gobert, Nathalie Hennuyer iD, Gaetan Herinckx, Maëla Pautric und 8 weitere

Angewandte Chemie International Edition · 2025

DOI: 10.1002/anie.202500518 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Angewandte Chemie International Edition, 2025. Verfasst von Darius Mazhari Dorooee und 19 weiteren Autor:innen. Beteiligte Einrichtung: Medicinal Chemistry Research Group (CMFA), Louvain Drug Research Institute (LDRI), Université Catholique de Louvain, 73 Avenue Mounier, B1.73.10, Bru…. Hauptthemen laut MEDLINE: Coenzyme A Ligases, Enzyme Inhibitors. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Fondation contre le Cancer, l'Agence Nationale de la Recherche, French Community Of Belgium.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acyl‐coenzyme A synthetase long‐chain family member 4 (ACSL4), a pivotal enzyme in lipid metabolism, has emerged as a therapeutic target for ferroptosis‐related conditions and cancer. However, its reference inhibitor, rosiglitazone, has off‐target activity on peroxisome proliferator‐activated receptor gamma (PPARγ), a key regulator of lipid homeostasis. Here, the discovery of LIBX‐A401, a potent ACSL4 inhibitor derived from rosiglitazone devoid of PPARγ activity, is reported. Its binding to ACSL4 is ATP‐dependent, stabilizing the C‐terminal domain and altering the fatty acid gate region, as shown by Hydrogen‐Deuterium Exchange Mass Spectrometry. Photoaffinity labeling identified A329 within the fatty acid binding site, while molecular dynamics and mutagenesis highlighted Q302 as critical for LIBX‐A401 binding. LIBX‐A401 exhibits anti‐ferroptotic properties in cells, supported by target engagement. These findings establish LIBX‐A401 as a valuable tool to study ACSL4 in ferroptosis and cancer, while its elucidated binding mode paves the way for the rational design of improved inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Coenzyme A LigasesEnzyme InhibitorsHumansBinding SitesFerroptosisLong-Chain-Fatty-Acid-CoA LigaseMolecular Structure

Stichwörter der Autor:innen

ACSL4 inhibitorsFerroptosisHydrogen Deuterium Exchange (HDx) mass spectrometryParkinson's diseasePhotoaffinity labeling

Substanzen

Coenzyme A LigasesEnzyme InhibitorsLong-Chain-Fatty-Acid-CoA Ligase

Autor:innen und Institutionen

  • Medicinal Chemistry Research Group (CMFA), Louvain Drug Research Institute (LDRI), Université Catholique de Louvain, 73 Avenue Mounier, B1.73.10, Brussels, 1200, Belgium.
  • Univ. Lille, Inserm, CHU Lille, UMR-S-U1172 - LilNCog - Lille Neuroscience & Cognition, Lille, F-59000, France.
  • MASSPROT Platform, de Duve Institute, Université Catholique de Louvain, Brussels, Belgium.
  • INSERM, CHU Lille, U-1286 - INFINITE - Institute for Translational Research in Inflammation, Université de Lille, Lille, F-59000, France.
  • Ludwig Institute for Cancer Research, Brussels, Belgium.
  • de Duve Institute, Université catholique de Louvain, Brussels, Belgium.

ORCID-Profile: Darius Mazhari Dorooee, Séverine Ravez, Didier Vertommen, Nicolas Renault, Nicolas Papadopoulos, Romain Marteau, Karine Porte, Nathalie Hennuyer, David Devos, Bart Staels, Patricia Melnyk, Stefan N Constantinescu, Raphaël Frédérick, Jamal El Bakali

Förderung

  • Fondation contre le Cancer
  • l'Agence Nationale de la Recherche
  • French Community Of Belgium
  • Belgian Fonds National de la Recherche Scientifique
  • Télévie
  • Région Hauts-de-France

Zitieren

APA

Mazhari Dorooee, D., Ravez, S., Vertommen, D., Renault, N., Papadopoulos, N., Marteau, R., Charnelle, E., Porte, K., Gobert, A., Hennuyer, N., Herinckx, G., Pautric, M., Jonneaux, A., Devedjian, J. C., Devos, D., Staels, B., Melnyk, P., Constantinescu, S. N., Frédérick, R., & El Bakali, J. (2025). LIBX‐A401: A Novel Selective Inhibitor of Acyl‐CoA Synthetase Long Chain Family Member 4 (ACSL4) and Its Binding Mode. Angewandte Chemie International Edition. https://doi.org/10.1002/anie.202500518

Vancouver

Mazhari Dorooee D, Ravez S, Vertommen D, Renault N, Papadopoulos N, Marteau R, et al. LIBX‐A401: A Novel Selective Inhibitor of Acyl‐CoA Synthetase Long Chain Family Member 4 (ACSL4) and Its Binding Mode. Angewandte Chemie International Edition. 2025. doi:10.1002/anie.202500518

BibTeX
@article{MazhariDorooee2025,
  author = {Mazhari Dorooee, Darius and Ravez, Séverine and Vertommen, Didier and Renault, Nicolas and Papadopoulos, Nicolas and Marteau, Romain and Charnelle, Emeline and Porte, Karine and Gobert, Alexandre and Hennuyer, Nathalie and Herinckx, Gaetan and Pautric, Maëla and Jonneaux, Aurélie and Devedjian, Jean Christophe and Devos, David and Staels, Bart and Melnyk, Patricia and Constantinescu, Stefan N and Frédérick, Raphaël and El Bakali, Jamal},
  title = {LIBX‐A401: A Novel Selective Inhibitor of Acyl‐CoA Synthetase Long Chain Family Member 4 (ACSL4) and Its Binding Mode},
  journal = {Angewandte Chemie International Edition},
  year = {2025},
  doi = {10.1002/anie.202500518}
}
Kostenlos starten →